


-16-

WE CLAIM:

1. A compound selected from the group consisting of:



-17-

wherein:

m is 1 or 2;

R and R¹ are OH or SO₂R¹¹ provided that one and only one of R or R¹ must be and is SO₂R¹¹;

5 R² and R³ are OH, OCOC(CH₃)₃ or SO₂R¹¹ provided that one and only one of R² or R³ must be and is SO₂R¹¹;

R⁴ and R⁵ are OH, OCH₃ or SO₂R¹¹ provided that one and only one of R⁴ or R⁵ must be and is SO₂R¹¹;

R⁶ is H, OH, OPO(OH)₂, I or SO₂R¹¹ and R¹⁰ is H, CH(CH₃)₂ or

10 SO₂R¹¹ provided that one and only one of R⁶ or R¹⁰ must be and is SO₂R¹¹;

R⁷ and R⁸ are both methyl or combine with the nitrogen to which they are attached to form a pyrrolidinyl ring;

R⁹ is CH₃ or CH₂Cl;

R¹¹ is C₁-C₆ alkyl, C₁-C₆ alkoxy, NR¹²R¹³, CF₃ or CH₂CF₃;


15 X is CO or O;

R¹² is C₁-C₆ alkyl or phenyl; and


R¹³ is H, C₁-C₆ alkyl or phenyl; or a pharmaceutical salt thereof.

-18-

2. The compound of claim 1 selected from the group consisting of:



-19-



or a pharmaceutical salt thereof.

3. The compound of claim 2 wherein R¹¹ is C₁-C₄ alkyl, CF₃ or NR¹²R¹³

5 and R¹² is C₁-C₄ alkyl and R¹³ is H or C₁-C₄ alkyl.

4. The compound of claim 1 or 2 wherein R¹¹ is methyl, ethyl, cyclopropyl, CF₃, NHCH₃ or N(CH₃)₂.

-20-

5. The compound of any one of claims 1-4 wherein R¹¹ is methyl or N(CH₃)₂.
5. The compound of any one of claims 1-5 wherein R¹¹ is methyl.
7. The compound of any one of claims 1-5 wherein R¹¹ is N(CH₃)₂;
8. The compound of any one of claims 1-7 which is the hydrochloride salt.
10. A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of any one of claims 1-8.
15. A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of any one of claims 1-8.
20. A compound of any one of claims 1-8 for use in treating endometriosis and/or uterine leiomyoma.